Loading...
  • marker
  • These results suggest that CSF neopterin, although not disease-specific, may be useful as a surrogate marker for the presence of AIDS dementia complex and its response to antiviral therapy. (docme.ru)
  • Ratio
  • The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months. (nih.gov)
  • Serum measurements of neopterin, kyn/trp ratio and neutralizing antibodies (NAbs) were obtained before treatment (i.e., at baseline) and 48 hours post-injection every 3 months thereafter. (nih.gov)
  • patients
  • In the patients with AIDS dementia complex, CSF neopterin concentrations correlated with severity of disease and decreased in conjunction with clinical improvement following treatment with zidovudine. (docme.ru)
  • Consequently, we assayed neopterin in the CSF and serum of patients at various stages of ADC as well as those with other neurological complications of HIV- 1 infection. (docme.ru)
  • levels
  • We also assessed the confounding influences of blood-brain barrier impairment and CSF pleocytosis as well as the effects of treatment with zidovudine (ZDV) (also azidothymidine or AZT) on CSF neopterin levels. (docme.ru)
  • analyses
  • Mann-Whitney analyses showed that neopterin values were always higher in the HD-group vs the LD-one at each time point (p = 0.046) apart from months 21 and 24 of treatment period (TP). (nih.gov)
  • therapy
  • Neopterin values were higher (p = 0.046) in the HD-compared to the LD-group at every time point with the exclusion of months 21 and 24 of therapy. (nih.gov)